Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts

Background Carbonic anhydrase IX (CAIX) is a membrane spanning protein involved in the enzymatic regulation of tumor acid-base balance. CAIX has been shown to be elevated in a number of hypoxic tumor types. The purpose of this study was to determine the efficiency of intact and IgG fragments of cG250 to target CAIX in vivo in a hypoxic tumor model. Methodology/Principal Findings Conventional biodistribution studies were performed with 111In-DO3A-cG250, 111In-DO3A-F(ab')2-cG250 and 111In-DO3A-Fab-cG250. Additional ex vivo analysis of the tumor was performed with markers for tumor hypoxia, blood perfusion and endogenous CAIX expression. All four data sets were digitally correlated to determine the optimal agent for determining hypoxia in a HT29 colon cancer xenograft. The HT29 human colorectal tumor xenografts show strong CAIX expression in hypoxic areas of poor blood perfusion. The intact IgG had an initial high focal uptake at the periphery of these hypoxic regions and penetration into the areas of highest CAIX expression over the 7-day study period. The lower molecular weight antibody fragments had a faster uptake into areas of high CAIX expression, but had a much lower absolute uptake at the optimal imaging times. Conclusions/Significance For the clinical detection of hypoxia induced CAIX using cG250 antibody based agents, imaging with the intact IgG at 7 days post injection would allow for the most sensitive and accurate detection of CAIX.

[1]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[2]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[5]  H. Minn,et al.  Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer , 2009, British Journal of Cancer.

[6]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[7]  C. Ling,et al.  Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. , 2008, Cancer research.

[8]  K. Fujimori,et al.  Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.

[9]  A. Harris,et al.  Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.

[10]  A. Harris,et al.  Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[12]  Seppo Parkkila,et al.  BMC Cancer BioMed Central Research article Carbonic anhydrase IX in oligodendroglial brain tumors , 2008 .

[13]  R. Figlin,et al.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Donna Richardson,et al.  Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[16]  C. Ling,et al.  Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. , 2007, Cancer research.

[17]  J. Pastorek,et al.  Biodistribution and pharmacokinetics of 125I‐labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma , 2003, International journal of cancer.

[18]  A. Harris,et al.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[20]  J. Weinstein,et al.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.

[21]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[22]  M. Flentje,et al.  Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  A. Harris,et al.  Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. , 2001, Cancer research.

[24]  K. Haustermans,et al.  Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas , 2006, Annals of surgery.

[25]  A. Harris,et al.  Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target , 2004, Cell cycle.

[26]  J. Schalken,et al.  Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. , 2004, Oncogene.

[27]  A. Scott,et al.  Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. , 2011, Urologic oncology.

[28]  J. Vermorken,et al.  Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. , 2007, The oncologist.

[29]  S. Batra,et al.  Pharmacokinetics and biodistribution of genetically engineered antibodies. , 2002, Current opinion in biotechnology.

[30]  S. Parkkila,et al.  Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. , 2005, World journal of gastroenterology.

[31]  J. Humm,et al.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.

[32]  Charles C Wykoff,et al.  DEC1 (STRA13) protein expression relates to hypoxia‐ inducible factor 1‐alpha and carbonic anhydrase‐9 overexpression in non‐small cell lung cancer , 2003, The Journal of pathology.

[33]  J. Pastorek,et al.  Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. , 2001, Journal of hepatology.

[34]  N. James,et al.  Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. , 2004, Oncology Report.

[35]  N. Bander,et al.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.

[36]  F. Buchegger,et al.  Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice , 1983, The Journal of experimental medicine.

[37]  W. Sly,et al.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. , 2001, The American journal of pathology.

[38]  J. Pastorek,et al.  Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. , 1997, Gastroenterology.

[39]  D. Solit,et al.  Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. , 2004, Methods in enzymology.